Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study.
COVID19
Immune Thrombocytopenia
SARS-CoV-2
vaccine
Journal
Mediterranean journal of hematology and infectious diseases
ISSN: 2035-3006
Titre abrégé: Mediterr J Hematol Infect Dis
Pays: Italy
ID NLM: 101530512
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
02
2023
accepted:
18
04
2023
medline:
14
5
2023
pubmed:
14
5
2023
entrez:
14
5
2023
Statut:
epublish
Résumé
Several infections and vaccinations can provoke immune thrombocytopenia (ITP) onset or relapse. Information on ITP epidemiology and management during the Covid-19 pandemic is scarce. In a large monocenter ITP cohort, we assessed the incidence and risk factors for: 1) ITP onset/relapse after Covid19 vaccination/infection; 2) Covid19 infection. Information on the date/type of anti-Covid-19 vaccine, platelet count before and within 30 days from the vaccine, and date/grade of Covid-19 was collected via phone call or during hematological visits. ITP relapse was defined as a drop in PLT count within 30 days from vaccination, compared to PLT count before vaccination that required a rescue therapy OR a dose increase of an ongoing therapy OR a PLT count <30 ×10 Between February 2020 and January 2022, 60 new ITP diagnoses were observed (30% related to Covid-19 infection or vaccination). Younger and older ages were associated with a higher probability of ITP related to Covid19 infection (p=0.02) and vaccination (p=0.04), respectively. Compared to Covid-19-unrelated ITP, Infection- and vaccine-related ITP had lower response rates (p=0.03) and required more prolonged therapy (p=0.04), respectively. Among the 382 patients with known ITP at the pandemic start, 18.1% relapsed; relapse was attributed to Covid-19 infection/vaccine in 52.2%. The risk of relapse was higher in patients with active disease (p<0.001) and previous vaccine-related relapse (p=0.006). Overall, 18.3% of ITP patients acquired Covid19 (severe in 9.9%); risk was higher in unvaccinated patients (p<0.001). All ITP patients should receive ≥1 vaccine dose and laboratory follow-up after vaccination, with a case-by-case evaluation of completion of the vaccine program if vaccine-related ITP onset/relapse and with tempest initiation of antiviral therapy in unvaccinated patients.
Sections du résumé
Background And Objectives
UNASSIGNED
Several infections and vaccinations can provoke immune thrombocytopenia (ITP) onset or relapse. Information on ITP epidemiology and management during the Covid-19 pandemic is scarce. In a large monocenter ITP cohort, we assessed the incidence and risk factors for: 1) ITP onset/relapse after Covid19 vaccination/infection; 2) Covid19 infection.
Methods
UNASSIGNED
Information on the date/type of anti-Covid-19 vaccine, platelet count before and within 30 days from the vaccine, and date/grade of Covid-19 was collected via phone call or during hematological visits. ITP relapse was defined as a drop in PLT count within 30 days from vaccination, compared to PLT count before vaccination that required a rescue therapy OR a dose increase of an ongoing therapy OR a PLT count <30 ×10
Results
UNASSIGNED
Between February 2020 and January 2022, 60 new ITP diagnoses were observed (30% related to Covid-19 infection or vaccination). Younger and older ages were associated with a higher probability of ITP related to Covid19 infection (p=0.02) and vaccination (p=0.04), respectively. Compared to Covid-19-unrelated ITP, Infection- and vaccine-related ITP had lower response rates (p=0.03) and required more prolonged therapy (p=0.04), respectively. Among the 382 patients with known ITP at the pandemic start, 18.1% relapsed; relapse was attributed to Covid-19 infection/vaccine in 52.2%. The risk of relapse was higher in patients with active disease (p<0.001) and previous vaccine-related relapse (p=0.006). Overall, 18.3% of ITP patients acquired Covid19 (severe in 9.9%); risk was higher in unvaccinated patients (p<0.001).
Conclusions
UNASSIGNED
All ITP patients should receive ≥1 vaccine dose and laboratory follow-up after vaccination, with a case-by-case evaluation of completion of the vaccine program if vaccine-related ITP onset/relapse and with tempest initiation of antiviral therapy in unvaccinated patients.
Identifiants
pubmed: 37180204
doi: 10.4084/MJHID.2023.029
pii: mjhid-15-1-e2023029
pmc: PMC10171210
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e2023029Déclaration de conflit d'intérêts
Competing interests: The authors declare no conflict of Interest.
Références
Exp Hematol Oncol. 2021 Jul 15;10(1):42
pubmed: 34266487
Leukemia. 2022 Oct;36(10):2548-2550
pubmed: 35963940
Blood Adv. 2021 Jul 13;5(13):2794-2798
pubmed: 34255033
Rinsho Ketsueki. 2021;62(11):1639-1642
pubmed: 34866090
Rheumatology (Oxford). 2021 Oct 9;60(SI):SI59-SI67
pubmed: 33369663
Lupus. 2021 Aug;30(9):1515-1521
pubmed: 34053365
Br J Haematol. 2021 Nov;195(3):365-370
pubmed: 34075578
Open Forum Infect Dis. 2021 Jun 24;8(7):ofab343
pubmed: 34307734
Kidney Int Rep. 2021 Dec;6(12):2969-2978
pubmed: 34632166
Ann Hematol. 2020 Jun;99(6):1205-1208
pubmed: 32296910
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Blood Adv. 2019 Dec 10;3(23):3829-3866
pubmed: 31794604
TH Open. 2021 Jul 30;5(3):e315-e318
pubmed: 34377889
Blood. 2022 Apr 21;139(16):2561-2565
pubmed: 35446373
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Cureus. 2021 Sep 13;13(9):e17942
pubmed: 34660131
J Clin Endocrinol Metab. 2022 May 17;107(6):e2324-e2330
pubmed: 35235663
Blood. 2009 Mar 12;113(11):2386-93
pubmed: 19005182
Pathobiology. 2021;88(1):15-27
pubmed: 33049751
RMD Open. 2021 Sep;7(3):
pubmed: 34493645
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Stem Cell Investig. 2021 Jul 09;8:14
pubmed: 34386543
Clin Rheumatol. 2022 May;41(5):1603-1609
pubmed: 35378658
Nature. 2020 Jan 8;:
pubmed: 33408356
Blood Adv. 2022 Mar 22;6(6):1637-1644
pubmed: 34941989
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296211073920
pubmed: 35108113
PLoS One. 2021 Mar 18;16(3):e0248671
pubmed: 33735911
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Vaccine. 2021 Jun 8;39(25):3329-3332
pubmed: 34006408
Immunology. 2022 Apr;165(4):386-401
pubmed: 34957554
Pediatrics. 2020 Aug;146(2):
pubmed: 32439817
Arch Dis Child. 2001 Mar;84(3):227-9
pubmed: 11207170
PLoS One. 2022 Oct 27;17(10):e0275718
pubmed: 36301805
SN Compr Clin Med. 2021;3(12):2389-2392
pubmed: 34308259
J Hepatol. 2022 Sep;77(3):653-659
pubmed: 35461912
J Autoimmun. 2011 Feb;36(1):4-8
pubmed: 20708902
Blood. 2022 Mar 10;139(10):1564-1574
pubmed: 34587251
Mediterr J Hematol Infect Dis. 2021 May 01;13(1):e2021032
pubmed: 34007420
Lancet. 2021 Apr 10;397(10282):1351-1362
pubmed: 33798499
Nat Rev Rheumatol. 2021 Feb;17(2):71-72
pubmed: 33339986
Blood Adv. 2019 Nov 26;3(22):3780-3817
pubmed: 31770441
Immunol Res. 2014 Dec;60(2-3):226-35
pubmed: 25427992
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Cureus. 2022 Jul 5;14(7):e26582
pubmed: 35815306
Clin Microbiol Infect. 2020 Jul;26(7):954-956
pubmed: 32229288
J Hematol Oncol. 2021 Oct 14;14(1):168
pubmed: 34649563
Am J Trop Med Hyg. 2021 Feb 19;104(4):1188-1201
pubmed: 33606667